Menlo Park, Calif.– Octave Bioscience, a company at the forefront of precision care for neurodegenerative diseases, has announced significant additions to its medical leadership team as it aims to accelerate the adoption of data-driven, personalized care in multiple sclerosis (MS) and related conditions. The company has appointed Dr. Jennifer Graves as Senior Medical Director, Dr. Darin Okuda as Senior Medical Advisor, and promoted Dr. Terrie Livingston to Vice President of Medical Affairs.
The new leadership brings deep clinical and scientific expertise to Octave’s mission of transforming how neurodegenerative diseases are understood, monitored, and treated. Their combined knowledge is expected to strengthen Octave’s ability to deliver biomarker-based tools and digital solutions that offer clinicians actionable insights, enabling more precise and timely therapeutic interventions.
Dr. Graves, a professor of neurosciences and Vice Chair of Human Clinical Research at UC San Diego, is also the Division Chief of Neuroimmunology and director of multiple sclerosis clinics at several institutions including UCSD and the San Diego VA Hospital. She noted that neurology is entering a new era, with precision biomarkers and digital technologies reshaping clinical decision-making. “Treating to target with a serological test will transform the field,” she said, referencing her early collaboration with Octave on pilot studies.
Dr. Okuda, a professor of neurology at The University of Texas Southwestern Medical Center and a specialist in MS and related disorders, emphasized the importance of translating scientific advancements into practical care. He said that the widespread availability of the Octave MSDA Test is allowing clinicians to intervene earlier in the disease course, offering real hope to patients. “We’re not just advancing innovation, we’re accelerating its reach,” he said.
Dr. Livingston, who now leads the company’s medical affairs division, emphasized her focus on advancing Octave’s ability to quantify disease activity and progression. “Our goal is to continue setting new standards of care by delivering actionable, data-driven insights that empower patients and guide optimal treatment decisions,” she said.
CEO Doug Biehn described the expansion as a pivotal moment for the company. “We are seeing strong adoption of our solutions across physicians, pharma, and payers,” he said. “This medical leadership team validates our vision and positions us to drive broad market adoption of precision neurology.”
Octave Bioscience will showcase its latest innovations at the CMSC Annual Meeting in Phoenix from May 28 to 31. The company will present five research posters highlighting advances in fluid biomarkers, and attendees can learn how the Octave MSDA Test is shaping the future of MS care through more personalized and timely treatment strategies.
